Literature DB >> 26346137

18F-FDG PET/CT in the post-operative monitoring of patients with adrenocortical carcinoma.

A Ardito, C Massaglia, E Pelosi1, B Zaggia, V Basile, R Brambilla1, F Vigna-Taglianti1, E Duregon1, V Arena1, P Perotti, D Penna1, M Terzolo.   

Abstract

CONTEXT: The role of (18)F-labeled 2-fluoro-2-deoxy-d-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) in the post-operative monitoring of patients with adrenocortical carcinoma (ACC) is still unclear.
OBJECTIVE: To assess the accuracy of FDG PET/CT to diagnose ACC recurrence in a real world setting. DESIGN AND METHODS: Retrospective evaluation of data of 57 patients with presumed ACC recurrence at CT scan who underwent FDG PET/CT within a median time of 20 days. We compared the results of either FDG PET/CT or CT with a gold standard confirmation of recurrence (positive histopathology report of removed/biopsied lesions or radiological progression of target lesions at follow-up) to assess their diagnostic performance at different body sites to correctly categorize target lesions. We also assessed whether FDG PET/CT findings may be useful to inform the management strategy.
RESULTS: In 48 patients with confirmed ACC recurrence, we found that FDG PET/CT had lower sensitivity than CT in diagnosing liver and lung recurrences of ACC. FDG PET/CT had higher specificity than CT in categorizing liver lesions. FDG PET/CT had a greater positive likelihood ratio than CT to identify liver and abdominal ACC recurrences. The management strategy was changed based on FDG PET/CT findings in 12 patients (21.1%).
CONCLUSIONS: The greater sensitivity of CT may be partly expected due the specific inclusion criteria of the study; however, the greater specificity of FDG PET/CT was particularly useful in ruling out suspected ACC recurrences found by CT. Thus, use of FDG PET/CT as a second-line test in the post-operative surveillance of ACC patients following CT finding of a potential recurrence may have a significant impact on patient management.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26346137     DOI: 10.1530/EJE-15-0707

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  PET Scans With 18F-Fluorodeoxyglucose to Diagnose Adrenal Tumors-Reply.

Authors:  David Taïeb; Karel Pacak
Journal:  JAMA       Date:  2017-10-24       Impact factor: 56.272

Review 2.  Update on advances in molecular PET in urological oncology.

Authors:  Kazuhiro Kitajima; Shingo Yamamoto; Kazuhito Fukushima; Ryogo Minamimoto; Takao Kamai; Hossein Jadvar
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

Review 3.  PET-CT and PET-MR in urological cancers other than prostate cancer: An update on state of the art.

Authors:  Abdul Razik; Chandan Jyoti Das; Sanjay Sharma
Journal:  Indian J Urol       Date:  2018 Jan-Mar

Review 4.  Imaging features of adrenal masses.

Authors:  Domenico Albano; Francesco Agnello; Federico Midiri; Giusy Pecoraro; Alberto Bruno; Pierpaolo Alongi; Patrizia Toia; Giuseppe Di Buono; Antonino Agrusa; Luca Maria Sconfienza; Salvatore Pardo; Ludovico La Grutta; Massimo Midiri; Massimo Galia
Journal:  Insights Imaging       Date:  2019-01-25

5.  Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity.

Authors:  Diego A S Toesca; Amanda J Koong; Rie von Eyben; Albert C Koong; Daniel T Chang
Journal:  Adv Radiat Oncol       Date:  2018-05-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.